Aurobindo Pharma Ltd News

Stocks to Watch today: ACME Solar, Gravita India, Kalpataru, Raymond Realty

Stocks to Watch today, March 13: Aurobindo Pharma, Godrej Properties, KPI Green Energy, JK Lakshmi Cement, Max Financial Services, and Nectar Lifesciences are among the top stocks to remain in focus

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Nifty, Bank Nifty outlook; Aurobindo Pharma, ABB among top stock picks

Bank Nifty has to hold above 56,750 zones for a bounce towards 57,250 then 57,500 levels while a hold below the same could see some weakness towards 56,500 then 56,250 zones

Aurobindo arm launches Pomalidomide generic in US, adds to oncology line

Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio

Stocks to Watch today: Defence, OMCs, Aurobindo, GAIL, Lupin, NCC, HG Infra

Stocks to Watch today: Aurobindo Pharma, GAIL India, Lupin, NCC, HG Infra, Brigade Enterprises and Anupam Rasayan are among the stocks to watch today, March 02, 2026

Aurobindo Pharma shares rise 4% after incorporating Engenra Biologics arm

The newly formed entity will operate in the pharmaceuticals sector and has been set up to expand the company's contract manufacturing and other pharmaceutical manufacturing operations

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Aurobindo Pharma up 3% in weak market, rebounds 6% from Wednesday's low

Aurobindo's management maintains confidence in achieving an internal EBITDA margin target of 20-21 per cent for FY26, supported by strong operating leverage and a diversified business model.

Voda Idea, DLF, RBL Bank among 18 F&O stocks to attract 15% higher margin

The NSE to levy 15% additional margin on equity derivatives in which top 10 clients account for more than 20% MWPL from March F&O series onwards; withdraws additional margin on Gold, Silver futures.

Aurobindo Pharma shares drop 5% amid reports of USFDA observations

According to media reports, the USFDA inspected its Unit-7 facility from January 28 to February 10, 2026, and issued observations at the end of the inspection

Aurobindo Pharma sinks 8%, stock hits over 3-month low post Q3 results

Aurobindo Pharma stock outlook: Eugia III resolution (in the backdrop of fresh observations) and the launch momentum across geographies would be key determinants, say analysts.

Stocks to Watch today: Aurobindo Pharma, BSE, Eternal, Pfizer, Trident

Stocks to watch today, Tuesday, February 10, 2026: Aurobindo Pharma, BSE, Eternal, Pfizer, and Trident shares are in focus on Tuesday

Aurobindo Pharma Q3FY26 results: Net profit rises 8% to ₹910 crore

Aurobindo Pharma on Monday said its consolidated net profit increased 8 per cent year-on-year to Rs 910 crore for the December quarter, led by robust sales in Europe and the US. The Hyderabad-based drug major reported a net profit of Rs 846 crore for the October-December period of the last fiscal year. Total revenue from operations increased to Rs 8,646 crore during the quarter as compared with Rs 7,979 crore in the year-ago period, the drug firm said in a statement. "Q3 reflected steady execution across Aurobindo's core businesses, supported by stable demand and the strength of our diversified product portfolio in key markets, including the US and Europe," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. Growth remained measured, with continued focus on operational discipline and a balanced approach to growth and profitability, he added. "As we progress our strategic initiatives, we remain cautious yet confident in our ability to support sustainable value creation

Q3 results: Pfizer, Zydus Lifesciences, Aurobindo Pharma, 181 more on Feb 9

Q3FY26 company results: Firms including GlaxoSmithKline Pharmaceuticals, The Ramco Cements, Linde India, Gulf Oil Lubricants, and Bata India are also to release their October-December earnings today

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,

Aurobindo Pharma soars 6% on huge volumes; here's what triggered the rally

Aurobindo Pharma stock up on Friday: The government has imposed a Minimum Import Price fixed at ₹2,216/kg for Penicillin G and is expected to provide a significant benefit to the company.

Stocks to Watch today, Jan 12: TCS, HCL Tech, DMart, Ireda, Vedanta

Stocks to watch on January 12, 2026: Stocks like TCS, HCL Technologies, Anand Rathi Wealth, and Infibeam Avenues will remain in focus as they will release their quarterly earnings today.

USFDA issues Form 483 with five observations to Aurobindo's Pharma unit

Aurobindo Pharma on Thursday said the US health regulator has issued a Form 483 with five observations after inspecting Andhra Pradesh-based Unit-IV of its subsidiary APL Healthcare. The US Food and Drug Administration (USFDA) inspected the unit from December 8 to December 17, 2025, the Hyderabad-based drug firm said in a regulatory filing. "At the end of the inspection, a 'Form 483' was issued with 5 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines," it added. The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, the drug firm said. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. Shares of Aurobindo Pharma were trading 0.83 per ..

Stocks to Watch today, Dec 15: Swiggy, BEL, Tata Elxsi, Aurobindo Pharma

Stocks to watch today, December 15, 2025: From Tata Elxsi to Aurobindo Pharma, here is a list of stocks to keep in focus

Motilal Oswal retains 'Buy' on Aurobindo Pharma as FY26-28 prospects shine

Tushar Manudhane, Vipul Mehta, and Eshita Jain, research analysts at MOFSL, value Aurobindo Pharma at 16 times 12-month forward earnings, assigning a target price of ₹1,430